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Abstract
Background: Fibrinogen storage disease (FSD) is a rare autosomal-dominant disorder caused by mutation in FGG,
encoding the fibrinogen gamma chain. Here we report the first Han Chinese patient with FSD, caused by de novo
fibrinogen Aguadilla mutation, and his response to pharmacologic management.
Case presentation: Epistaxis and persistent clinical-biochemistry test-result abnormalities prompted liver biopsy
in a boy, with molecular study of FGG in him and his parents. He was treated with the autophagy enhancer
carbamazepine, reportedly effective in FSD, and with ursodeoxycholic acid thereafter. Inclusion bodies in
hepatocellular cytoplasm stained immune-histochemically for fibrinogen. Selective analysis of FGG found the
heterozygous mutation c.1201C > T (p.Arg401Trp), absent in both parents. Over more than one year’s follow-up,
transaminase and gamma-glutamyl transpeptidase activities have lessened but not normalized.
Conclusion: This report expands the epidemiology of FSD and demonstrates idiosyncrasy in response to oral
carbamazepine and/or ursodeoxycholic acid in FSD.
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Background
Fibrinogen, synthesized in the liver, is the focal point of
the coagulation cascade. The mature circulating molecule
is a dimer, with each half composed of 3 polypeptide
chains (Aα, Bβ, and γ) encoded by 3 different genes.
Defects in these genes can cause hypofibrinogenemia with
or without abnormal circulating fibrinogen, resulting in
coagulopathy with bleeding and thrombosis as well as in
renal-predominant amyloidosis. When mutation in the
fibrinogen gamma chain gene (FGG) results not only in
hypofibrinogenemia but also in accumulation of fibrino-
gen within endoplasmic reticulum (ER) of hepatocytes
and varying degrees of liver disease, fibrinogen storage
disease (FSD) can be diagnosed [1].
Since the first report of FSD due to FGG mutation
[2], FSD has been found in Europe, America, Japan,
Saudi Arabia, and Turkey [3–11], but not in China.
Data on medical management of FSD are few [10, 12, 13];
carbamazepine (CBZ) and ursodeoxycholic acid (UDCA)
may be useful [12, 13]. We report the first Han Chinese
patient with FSD confirmed by morphologic studies and
molecular analysis and describe his response to CBZ and
UDCA administration.
Case presentatation
A 2-year-old boy was referred for evaluation. He was born
to healthy parents at 34 weeks’ gestation (weight 2450 g).
At age 8 months, on hospitalization for bronchopneumo-
nia, mild clinical-biochemistry abnormalities suggesting
hepatocellular injury (“transaminitis”) were noted; these
remained after acute respiratory disease resolved. At age
20 months, on evaluation for epistaxis, mild transaminitis
and hypofibrinogenemia were found. Transaminitis and a
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prolonged coagulation time persisted even after vitamin
K1 injection.
The patient weighed 13.0 kg (50–80 percentile); he
was 87 cm tall (25–50 percentile). He was not pale. The
liver was palpable 3.5 cm below the right costal margin.
The spleen was not palpable. Abdominal ultrasonog-
raphy showed mild hepatomegaly. Complete blood count
results were normal. Clinical-biochemistry studies found
elevated serum activities of alanine aminotransferase
(ALT, 529.6 IU/L; expected < 60), aspartate aminotransfer-
ase (AST, 298.2 IU/L; < 60), and γ-glutamyl transpeptidase
(GGT, 59 IU/L; < 50). Markers of liver protein synthesis,
including total protein (TP, 65 g/L) and albumin (ALB,
49 g/L), were within expected ranges, as were immuno-
globulin and ceruloplasmin values. No serologic evi-
dence of active hepatitis A, B, C, or E infection was
identified. Profiles of plasma amino acids and urine or-
ganic acids were normal. No antinuclear antibodies or
antibodies against liver-kidney microsomes (type 1) or
smooth muscle could be demonstrated.
Profound hypofibrinogenemia (fibrinogen 0.29 g/L;
2.38–4.98) was found, as were a prolonged prothrombin
time (PT, 17.1 s; 9.0–14.5) and activated partial
thromboplastin time (APTT, 42.8 s; 25–39). No
clinical-biochemistry evidence of hepatobiliary injury or
coagulopathy was identified in either parent.
The patient underwent liver core needle biopsy with
informed consent of the parents. The biopsy specimen
was routinely fixed in phosphate-buffered formalin,
processed into paraffin, and sectioned for staining
(hematoxylin-eosin [H&E]; periodic acid–Schiff tech-
nique with and without diastase predigestion) and im-
munostaining (antibodies against alpha-1-antitrypsin,
alpha-1-antichymotrypsin, and fibrinogen). Fixation for
ultrastructural study was not undertaken.
FSD was suspected on clinicopathologic grounds.
With the approval of the ethics committee on human
research of the Jinshan Hospital of Fudan University
and informed consent of the parents, peripheral-blood
samples were obtained from the patient and his par-
ents. Genomic DNA was extracted routinely and exons
8 and 9 of FGG, which all previous FSD mutations have
been located in [14], were amplified by polymerase
chain reaction (conditions available on request). Purified
PCR products were directly sequenced on an ABI Prism
3730 Genetic Analyzer (Applied Biosystems, Foster City,
CA). The oligonucleotide primers used were: Exon 8,
forward 5′-AGGGTCAGCATGTATGGTT-3′ and reverse
5′-TCCACTTCCAGTTTCAAAGAA-3′; exon 9, forward
5′-ACTGGCAATGCACTTCGTAA-3′ and reverse 5′-
AAAAAGGAAGAAACTTTCAG AGAA-3′. Sequence
analysis used BIOEDIT software (North Carolina State
University, Raleigh, NC) with NM_000509.4 as refer-
ence sequence. Variations were named according to the
guidelines of the Human Genome Variation Society.
Commercial testing was carried out to exclude the pos-
sibility of alternative paternity.
Guidelines for therapy of FSD are not defined. With
the informed consent of the parents, we administered
CBZ orally as described [12], with close follow-up.
Twice-daily doses began at 25 mg (50 mg/d) and rose
gradually to 125 mg (250 mg/d; 19.2 mg kg−1d−1) in
2 months, with clinical-biochemistry monitoring every 2
to 4 weeks. The dose was maintained for 6 months.
Persistently elevated ALT and GGT levels and the worry
of CBZ-related toxicity led us to decrease the dose of
CBZ gradually from day 240 (Fig. 1). After about
300 days’ administration of CBZ, substantially elevated
GGT prompted addition of UDCA (20 mg kg-1 d-1,
divided twice), reportedly useful in the management of
FSD [13].
Mild portal-tract fibrosis and slight chronic inflamma-
tion were present, with rare necrotic individual hepato-
cytes. Hepatocyte cytoplasm was finely granular. Scattered
hyaline, eosinophilic inclusion bodies up to 6 μ in diam-
eter were set off by focal cytoplasmic edema (Fig. 2a).
These stained only palely on periodic acid–Schiff staining;
staining was not altered by diastase pretreatment. On
immunostaining, the bodies stained for fibrinogen (Fig. 2b)
but not alpha-1-antitrypsin or alpha-1-antichymotrypsin.
FSD was diagnosed.
FGG sequence analysis in the patient detected heterozy-
gosity for a known disease-causing mutation (c.1201C > T/
p.Arg401Trp) (Additional file 1: Supplementary data),
predicted to yield fibrinogen Aguadilla [3, 6–8, 10–13]. No
mutation was found in either parent. Commercial testing
found non-FGG marker inheritance patterns consistent
with paternity as declared.
CBZ treatment led initially to a decrease in transami-
nitis (Fig. 1). A serum concentration of CBZ 4 months
after treatment began was 5.59 g/ml. Unfortunately, ALT
Fig. 1 Evolution of ALT and GGT activities after CBZ administration;
horizontal lines, upper bounds of expected ALT and GGT values
(60 and 50 U/L respectively). 0, X axis: Day immediately before CBZ
begun. Arrow 1, serum concentration of CBZ determined (5.59 μg/ml).
Arrow 2, ursodeoxycholic acid begun (20 mg kg−1 d−1)
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values had not returned to expected ranges (below upper
horizontal line, Fig. 1) on about 300-day follow-up.
When serum GGT activity reached 13× upper bounds of
expected ranges, ursodeoxycholic acid was added; GGT
levels, but not ALT levels, rapidly fell. To date, both
ALT and GGT have not returned to ranges expected in
health.
During the follow-up period, growth has been nor-
mal; side effects of CBZ (e.g., hypoleukocytosis or
thrombocytopenia, hematuria) have not been identified on
routine whole blood cell count and urinalysis, and neither
arrhythmia nor intraocular haemorrhage was revealed by
6-monthly electrocardiography and ophthalmoscopy.
Conclusion
The rare autosomal-dominant hereditary disorder FSD
was first described in German families in 1981 [15]. At
this writing, genetically confirmed cases are recorded in
16 families: Information on medical management is scant
[10, 12, 13]. Here we report the first histopathologically
and genetically documented case of FSD from China, in a
Han Chinese boy whose disorder has responded only par-
tially to CBZ and UDCA therapy.
Congenital hypofibrinogenemia can be caused by mu-
tations in FGA, FGB, or FGG. However, only 6 muta-
tions (listed in Table 1, with predicted sequences) in the
FGG sequence encoding the fibrinogen γ chain residues
between 310 and 401 (including signal peptide) are
known to cause hypofibrinogenemia and hepatocyte ER
storage of abnormal fibrinogen [2–13]. Among them,
c.1201C > T (fibrinogen Aguadilla) is repeatedly encoun-
tered [3, 6–8, 10–13]. It can be inherited or de novo,
that is, not detected in either parent, as our patient, with
genetic evidence supporting declared paternity. This site
within FGG appears peculiarly susceptible to mutation
likely because the site involves a CpG sequence which is
subject to hypermutation through methylation and dea-
midation of C to T [16].
Most FSD patients have been asymptomatic, with inci-
dental diagnosis during routine laboratory examination.
Aside from epistaxis, our patient had no obvious symp-
toms; his disorder was suspected only when clinical-
biochemistry abnormalities were noted and coagulation
parameters were assessed. Histological examination of a
liver-biopsy specimen found in hepatocellular cytoplasm
inclusion bodies that marked immunohistochemically
for fibrinogen.
Fig. 2 Liver. Palely eosinophilic intracytoplasmic inclusion bodies (a, H&E) mark at their margins on immunostaining for fibrinogen (b, anti-fibrinogen –
diaminobenzidine / hematoxylin). Original magnifications, both images, 1,000×
Table 1 Reported mutations resulting in fibrinogen storage disease
Name Nucleotide change Amino acid change (NM_000509.4) Amino acid change (originally described,
without signal peptide)
Brescia [2] c.928G > C p.Gly310Arg p.Gly284Arg
Aguadilla [3, 6–8, 10–13] c.1201C > T p.Arg401Trp p.Arg375Trp
Anger [4] c.1115_1129delGAGTTTATTACCAAG p.G372_Q376del p.G346_Q350del
AI DuPont [5] c.1018A > C p.Thr340pro p.Thr314pro
Pisa [9] c.1024G > A p.Asp342Asn p.Asp316Asn
Beograd [9] c.1174G > A p.Gly392Ser p.Gly366Ser
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However, some individuals who exhibit only hypofibri-
nogenemia harbor mutations that in family members are
associated with FSD [2, 8–11]. Retention of abnormal
proteins within ER may, but need not, lead to liver
disease; this has been attributed to variation in ER deg-
radation [17]. Background differences may influence re-
sponse to treatment. Two patients with FSD (fibrinogen
Aguadilla) who were given the autophagy-enhancing
agent CBZ responded well, with rapid normalization of
serum ALT activity (35 and 26 days) [13]. However, in our
patient gradually increased doses of CBZ, as described,
reduced transaminitis without effecting normalization.
The transient elevation of GGT activity during CBZ
administration may be related to toxicity of CBZ [18],
although this has not been seen in FSD patients before.
Given the absence of other liver disease, we ascribe in-
complete response in our patient to idiosyncrasy.
Treatment for 36 months with UDCA and vitamin E
also has been reported to normalize patient transaminase-
activity values [13]. We gave UDCA in response to the
GGT activity spike and to persistently abnormal ALT
activity after approximately 290 days of follow-up. GGT
activity decreased sharply after UDCA was begun, but to
date (about 70 days of follow-up at this writing after
UDCA begun) ALT activity is essentially unchanged. The
results may be associated with the short treated days and
need further observation.
We present our experience with FSD and its treatment
to advise colleagues that Han Chinese patients may
develop FSD; our patient is the first described from this
ethnic group, but others will likely be seen. We also wish
to temper possible enthusiasm for CBZ and UDCA
treatment of FSD by reporting that in our hands its
success has been, to date, incomplete.
Additional file
Additional file 1: Supplementary material: Figure. The information of
the mutation in the fibrinogen gamma chain gene (FGG) of the patient.
(BMP 685 kb)
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